LATAM Fabry Disease Market
- 2026 年市場規模
- USD 105.41 Mn
- 2033 年預估規模
- USD 165.92 Mn
- 年複合成長率 CAGR
- 6.9%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
LATAM Fabry Disease Market, By Therapy Type (Enzyme Replacement Therapy (Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Pegunigalsidase Alfa (PRX-102, Phase III)) Chaperon Therapy (Migalastat (Galafold Phase III)), Substrate Reduction Therapy (Lucerastat (Phase III), Venglustat (Phase III))), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals Pharmacies, Online pharmacies, Retail Pharmacies), By Geography (Latin America)
報告摘要
Fabry disease is an inherited disorder which is caused by accumulation for globotriaosylceramide, a type of fat, in the body’s cells. Fabry disease symptoms affect body parts which include a decreased ability to sweat, events of pain in hands and feet, difficulties with the gastrointestinal system, etc. Diagnosis for fabry disease includes test such as Deoxyribonucleic acid sequence analysis, enzyme assay analysis, etc.
Treatment for fabry disease includes intravenously administered enzyme replacement therapy or oral chaperone therapy, along with this it may also need lifestyle modifications and prophylactic medications. Sometimes doctors also refer drugs to relieve pain, medicine for stomach problems, blood thinners or other drugs for an irregular heartbeat or other heart problems, blood pressure medicine, which also helps to protect kidneys. If fabry disease has caused serious kidney damage, dialysis or a kidney transplant is needed for treatment.
Market Dynamics
Survey regarding achievements or learning about fabry disease, is expected to drive growth of the LATAM fabry disease market. For instance, according to data published on June 20, 2022, by Orphanet Journal of Rare Diseases, a team of researchers had done 20 years of Fabry Outcome Survey that focused to broaden the understanding of fabry disease such as to know about the insights, achievements, and learning more about the development of fabry disease, effects of treatment, etc. according to same Route of Administration population suffering from fabry disease has reported cardiovascular problem and it was more common type of problem reported in male and female in with fabry disease in Latin America.
Updated guidelines by regulatory bodies for the development of drugs used in the treatment of fabry disease is expected to drive the LATAM fabry disease market growth. For instance, in August, 2019, the U.S. Food and Drug Administration announced the availability the draft guidance for the industries, to develop drugs for the treatment of fabry disease. This draft guidance describes the FDA’s current recommendations regarding eligibility criteria, trial design considerations, and efficacy endpoints to be used in clinical development programs of investigational drugs to treat fabry disease.
Key features of the study
• This report provides in-depth analysis of the LATAM fabry disease market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the LATAM fabry disease market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Amicus Therapeutics, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Mendelics, Takeda Pharmaceuticals U.S.A., Inc, Teva pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, Moderna Therapeutics Inc, and Resverlogix.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The LATAM fabry disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the LATAM fabry disease market
LATAM Fabry Disease Market Segmentation
• By Therapy Type (Revenue, USD Mn, 2020 - 2033)
o Enzyme Replacement Therapy
Agalsidase Beta (Fabrazyme)
Agalsidase Alfa (Replagal)
Pegunigalsidase Alfa (PRX-102, Phase III)
o Chaperon Therapy
Migalastat (Galafold Phase III)
o Substrate Reduction Therapy
Lucerastat (Phase III)
Venglustat (Phase III)
• By Route of Administration Insights (Revenue, USD Mn, 2020 - 2033)
o Oral
o Parental
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
o Hospitals Pharmacies
o Retail Pharmacies
o Online pharmacies
• By Country Insights (Revenue, USD Mn, 2020 - 2033)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Key Players
o Amicus Therapeutics, Inc.
o Sanofi-Aventis U.S. LLC
o GlaxoSmithKline plc
o Mendelics
o Takeda Pharmaceuticals U.S.A., Inc
o Teva pharmaceutical Industries Ltd
o Pfizer Inc.
o Novartis AG
o Moderna Therapeutics Inc
o Resverlogix
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Therapy Type
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Country
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Recent Product Launch/Approval
o Key Strategies Adopted by Market Players
o PEST Analysis
o Epidemiology
o Mergers and Acquisitions
4. LATAM Fabry Disease Market, By Therapy Type, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Enzyme Replacement Therapy
Agalsidase Beta (Fabrazyme)
Agalsidase Alfa (Replagal)
Pegunigalsidase Alfa (PRX-102, Phase III)
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Chaperon Therapy
Migalastat (Galafold Phase III)
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Substrate Reduction Therapy
Lucerastat (Phase III)
Venglustat (Phase III)
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
5. LATAM Fabry Disease Market, By Route of Administration, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
6. LATAM Fabry Disease Market, By Distribution Channel, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Hospitals Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Online pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
7. LATAM Fabry Disease Market, By Country, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Country, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2020 – 2033
o Latin America
Brazil
o Market Size and Forecast, By Therapy Type, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Route of Administration, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
Mexico
o Market Size and Forecast, By Therapy Type, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Route of Administration, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
Argentina
o Market Size and Forecast, By Therapy Type, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Route of Administration, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
Rest of Latin America
o Market Size and Forecast, By Therapy Type, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Route of Administration, 2021 – 2033, (USD Mn)
o Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Amicus Therapeutics, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Sanofi-Aventis U.S. LLC
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
GlaxoSmithKline plc
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Mendelics
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Takeda Pharmaceuticals U.S.A., Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Teva pharmaceutical Industries Ltd
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Pfizer Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Novartis AG
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Moderna Therapeutics Inc
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Resverlogix
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們